European Urology

Research Paper

Immunohistochemical Studies on the Expression of HLA Class I Antigens in Renal Cell Carcinoma: Comparison of Primary and Metastatic Tumor Tissue

Buszello H. · Ackermann R.

Author affiliations

Department of Urology, Heinrich Heine University, Düsseldorf, FRG

Related Articles for ""

Eur Urol 1994;25:158–163

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: August 11, 2017
Issue release date: 1994

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR

Abstract

HLA class I expression was studied in 43 specimens of normal renal tissue, 48 primary renal cell carciomas (RCCs), and 12 métastasés by immunofluorescence, using two different monoclonal antibodies (MoAbs; IOT2c, W6/32). Homogenous staining of all normal renal tissues was observed, as expected. From the panel of 48 renal tumors, 40 had a strong expression of HLA class I antigens when tested with both MoAbs, 7 tumors had only weak expression of HLA class I and were regarded as 'HLA class I negative', and 1 tumor showed homogenous staining when tested with one MoAb (IOT2c) but was negative when the other was used (W6/32). This was the only case in which different results with the two MoAbs were found. Reduced expression of HLA class I antigens was observed in 5/12 métastasés, and in 1 metastasis no expression of HLA class I could be seen. The staining chartacteristics of 10 métastasés in comparison with the respective primary tumors were as follows: same HLA class I score 7/10; loss of HLA class I 3/10; gain of HLA class 10/10. In RCC, a complete loss of HLA class I expression is a rare phenomena, which was observed in 0/48 primary tumors and in 1/12 métastasés. Reduced expression of HLA class I antigens occurs in about 15% of primary tumors but is more frequent (50%) in métastasés; however, if this is relevant for cytotoxicity by T lymphocytes is unknown.




Related Articles:


Article / Publication Details

Published online: August 11, 2017
Issue release date: 1994

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP